| Literature DB >> 27312135 |
Mei Liu1, Zhiyang Li1,2, Jingjing Yang3, Yanyun Jiang3, Zhongsi Chen1, Zeeshan Ali3, Nongyue He1, Zhifei Wang3.
Abstract
Breast cancer is the second leading cause of cancer death among women, and its related treatment has been attracting significant attention over the past decades. Among the various treatments, targeted therapy has shown great promise as a precision treatment, by binding to cancer cell-specific biomarkers. So far, great achievements have been made in targeted therapy of breast cancer. In this review, we first discuss cell-specific biomarkers, which are not only useful for classification of breast cancer subtyping but also can be utilized as goals for targeted therapy. Then, the innovative and generic-targeted biopharmaceuticals for breast cancer, including monoclonal antibodies, non-antibody proteins and small molecule drugs, are reviewed. Finally, we provide our outlook on future developments of biopharmaceuticals, and provide solutions to problems in this field.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27312135 PMCID: PMC6496337 DOI: 10.1111/cpr.12266
Source DB: PubMed Journal: Cell Prolif ISSN: 0960-7722 Impact factor: 6.831